Transplantation provides superior survival high risk myeloid malignancies in older patients

References

• Pease DF, Ross JA, Poynter JN, et al. Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. Cancer Epidemiol. 2015;39(2):222–228.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94(7):1127–1138.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-Intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39(30):3328–3339.
   PubMed Web of Science ®Google Scholar
• Kroger N, Sockel K, Wolschke C, et al. Comparison between 5-Azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol. 2021;39(30):3318–3327.
   PubMed Web of Science ®Google Scholar
• Ustun C, Le-Rademacher J, Wang HL, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33(11):2599–2609.
   PubMed Web of Science ®Google Scholar
• Uy GL, Mandrekar SJ, Laumann K, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017;1(5):331–340.
   PubMed Web of Science ®Google Scholar
• Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010;116(20):4077–4085.
   PubMed Web of Science ®Google Scholar
• Nand S, Othus M, Godwin JE, et al. A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and Post-Remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia (SWOG S0703): report on the poor risk patients. Blood. 2012;120(21):3584–3584.
   Web of Science ®Google Scholar
• Erba HP, Othus M, Walter RB, et al. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res. 2014;38(3):329–333.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Holtan SG, Wang T, et al. Composite GRFS and CRFS outcomes after adult alternative donor HCT. J Clin Oncol. 2020;38(18):2062–2076.
   PubMed Web of Science ®Google Scholar
• Grunwald MR, Zhang MJ, Elmariah H, et al. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021;5(4):975–983.
   PubMed Web of Science ®Google Scholar
• Perales MA, Tomlinson B, Zhang MJ, et al. Alternative donor transplantation for acute myeloid leukemia in patients aged >/=50 years: young HLA-matched unrelated or haploidentical donor? Haematologica. 2020;105(2):407–413.
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Eapen M, Ruggeri A, et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant. 2014;20(6):816–822.
   PubMed Web of Science ®Google Scholar
• Sandhu KS, Brunstein C, DeFor T, et al. Umbilical cord blood transplantation outcomes in acute myelogenous leukemia/myelodysplastic syndrome patients aged ≥70 Years . Biol Blood Marrow Transplant. 2016;22(2):390–393.
   PubMed Web of Science ®Google Scholar
• Ustun C. Is haploidentical HCT better than….? A wrong question for future studies. Biol Blood Marrow Transplant. October 01, 2019;25(10):e303–e304.
   Google Scholar
• Bashey A, Zhang X, Jackson K, et al. Comparison of outcomes of hematopoietic cell transplants from T-Replete haploidentical donors using Post-Transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched unrelated donors and HLA-Identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant. 2016;22(1):125–133.
   PubMed Web of Science ®Google Scholar
• Bejanyan N, Brunstein CG, Cao Q, et al. Similar survival after umbilical cord blood (UCB) and HLA-Matched adult donor transplantation by disease risk index (DRI) assignment. Blood. 2015;126(23):4375–4375.
   Web of Science ®Google Scholar
• Bejanyan N, Brunstein CG, Cao Q, et al. Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. Blood Adv. 2019;3(3):230–236.
   PubMed Web of Science ®Google Scholar
• Ustun C. Is haploidentical HCT better than…? a wrong question for future studies. Biol Blood Marrow Transplant. 2019;25(10):e303–e304.
   PubMedGoogle Scholar
• Canaani J, Savani BN, Labopin M, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018;93(2):246–253.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Shah MV, Saliba RM, et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24(6):1232–1236.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Woo Ahn K, Hu ZH, et al. Outcomes after umbilical cord blood transplantation for myelodysplastic syndromes. Biol Blood Marrow Transplant. 2017;23(6):971–979.
   PubMed Web of Science ®Google Scholar
• Eapen M, Brazauskas R, Hemmer M, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2(16):2095–2103.
   PubMed Web of Science ®Google Scholar
• Oran B, Ahn KW, Fretham C, et al. Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes. Transplant Cell Ther. 2021;27:921 e921–921 e910.
   Google Scholar
• Lipof J, Loh K, O’Dwyer K, et al. Allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Cancers (Basel). 2018;10(6):179.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249–3256.
   PubMed Web of Science ®Google Scholar
• Pamukcuoglu M, Bhatia S, Weisdorf DJ, et al. Hematopoietic cell transplant related toxicities and mortality in frail recipients. Biol Blood Marrow Transplant. 2019 Dec;25(12):2454–2460. doi: 10.1016/j.bbmt.2019.07.030. Epub 2019 Aug 5.
   PubMedGoogle Scholar
• Kennedy VE, Olin RL. Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol. 2021;8(11):e853–e861.
   PubMed Web of Science ®Google Scholar
• Derman BA, Kordas K, Ridgeway J, et al. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019;3(22):3488–3498.
   PubMed Web of Science ®Google Scholar
• Randall J, Keven K, Atli T, et al. Process of allogeneic hematopoietic cell transplantation decision making for older adults. Bone Marrow Transplant. 2016;51(5):623–628.
   PubMed Web of Science ®Google Scholar
• Foran JM, Sun Z, Claxton D, et al. Maintenance decitabine (DAC) improves Disease-Free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-Negative patients: ECOG-ACRIN (EA) E2906 randomized study. Blood. 2019;134(Suppl. 1):115–115.
   Google Scholar
• Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-Internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002.
   PubMed Web of Science ®Google Scholar
• Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133(13):1457–1464.
   PubMed Web of Science ®Google Scholar
• Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for Glucocorticoid-Refractory acute graft-versus-Host disease. N Engl J Med. 2020;382(19):1800–1810.
   PubMed Web of Science ®Google Scholar
• Jagasia M, Lazaryan A, Bachier CR, et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic Graft-Versus-Host disease. J Clin Oncol. 2021;39(17):1888–1898.
   PubMed Web of Science ®Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–2250.
   PubMed Web of Science ®Google Scholar
• Watkins B, Qayed M, McCracken C, et al. Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol. 2021;39(17):1865–1877.
   PubMed Web of Science ®Google Scholar
• Benjamin Tomlinson, Marcos de Lima, Christopher R. Cogle, Michael A. Thompson, David L. Grinblatt, Daniel A. Pollyea, Rami Komrokji, Gail J. Roboz, Michael R. Savona, Mikkael A. Sekeres, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Harry P. Erba, David P. Steensma, MD Bart L. Scott. Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Registry Transplant Cell Ther. March 01, 2020;26(3), SUPPLEMENT , S98–S99.
   Google Scholar
• Pagel JM, Othus M, Garcia-Manero G, et al. Rapid donor identification improves survival in High-Risk First-Remission patients with acute myeloid leukemia. J Clin Oncol Oncol Pract. 2020;16(6):e464–e475.
   Google Scholar
• Warlick ED, Ustun C, Andreescu A, et al. Blood and marrow transplant clinical trials network study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation. Cancer. 2021;127(23):4339–4347.
   PubMed Web of Science ®Google Scholar